[{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New small molecule to treat Alzheimer\\'s disease and Dravet syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Genentech"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven\\'s Verdiperstat Receives FDA May Proceed Letter To Initiate Trial In Amyotrophic Lateral Sclerosis Conducted By The Healey Center For ALS At Mass General","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nektar Therapeutics"},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Desmetramadol is G-Protein Biased Opioid Receptor Agonist: Syntrix","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Syntrix Pharmaceuticals"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Reports Positive Study Results for ET-101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Eton Pharmaceuticals"},{"orgOrder":0,"company":"TissueTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TissueTech Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. Food and Drug Administration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"TissueTech"},{"orgOrder":0,"company":"Travecta Therapeutics","sponsor":"TKS1","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Travecta Therapeutics Secures $15 Million in Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Travecta Therapeutics"},{"orgOrder":0,"company":"Axcella Health","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$60.1 million","upfrontCash":"Undisclosed","newsHeadline":"Axcella Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters\u2019 Option","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Axcella Health"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Reports Publication of International Patent Application for Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Cyclo Therapeutics"},{"orgOrder":0,"company":"Axial Biotherapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axial Biotherapeutics to Present Virtual Presentation at American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Axial Biotherapeutics, Inc"},{"orgOrder":0,"company":"Affinia Therapeutics","sponsor":"Atlas Venture","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Affinia Therapeutics Raises $60M in Series A Financing to Advance Rational Design AAV Platform and Transformative Gene Therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Affinia Therapeutics"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$76.0 million","upfrontCash":"Undisclosed","newsHeadline":"Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Autobahn Therapeutics"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Nan Fung Life Sciences","pharmaFlowCategory":"D","amount":"$32.0 million","upfrontCash":"Undisclosed","newsHeadline":"Engrail Therapeutics Raises $32 Million in Series A Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Engrail Therapeutics"},{"orgOrder":0,"company":"Vizient","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vizient Announces Novaplus Enhanced Supply Agreement with Pfizer for Six Essential Medications","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Vizient"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Reports on Eighteen Month Expanded Access Program in Single Alzheimer\u2019s Patient","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Cyclo Therapeutics"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$72.5 million","newsHeadline":"Sarepta and Codiak BioSciences to develop rare disease therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Codiak BioSciences"},{"orgOrder":0,"company":"PicnicHealth","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Roche, Genentech Employ PicnicHealth to Tap into MS Patient Data","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"PicnicHealth"},{"orgOrder":0,"company":"Pocono Coated Product","sponsor":"Nutriband","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nutriband Acquires Transdermal and Health Product Manufacturing Business","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Pocono Coated Product"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Eton Pharmaceuticals"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$415.0 million","upfrontCash":"$15.0 million","newsHeadline":"Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Scribe Therapeutics"},{"orgOrder":0,"company":"Advanced Neural Dynamics","sponsor":"Neuropathix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuropathix, Inc. Acquires Neuroprotective and Anticonvulsant Intellectual Property Estate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Advanced Neural Dynamics"},{"orgOrder":0,"company":"Kashiv Specialty Pharmaceuticals","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","amount":"$108.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amneal to Acquire Substantially all of Kashiv Specialty Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Kashiv Specialty Pharmaceuticals"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Engrail Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Engrail Therapeutics Acquires NeuroCycle Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Engrail Therapeutics"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Silo Pharma"},{"orgOrder":0,"company":"Alkido Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AIkido Granted Sublicense to Technology for Targeted Psilocybin Treatment of Neuro-Inflamed Tissue in Cancer Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Alkido Pharma"},{"orgOrder":0,"company":"Akome Biotech","sponsor":"Core One Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Core One Labs Reaches Definitive Agreement to Acquire Akome Biotech","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Akome Biotech"},{"orgOrder":0,"company":"Zylo Therapeutics","sponsor":"Silo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Silo Pharma and Zylo Enter Into Joint Venture Agreement to Focus on the Development of Ketamine using ZTI\u2019s Z-pod\u2122 Technology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Zylo Therapeutics"},{"orgOrder":0,"company":"Bexson Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Bexson Biomedical"},{"orgOrder":0,"company":"Core One Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Core One Labs"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"$5.0 million","newsHeadline":"Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Ginkgo Bioworks"},{"orgOrder":0,"company":"AIkido Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIkido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"AIkido Pharm"},{"orgOrder":0,"company":"Akome Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Akome Biotech"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Relmada Therapeutics","pharmaFlowCategory":"D","amount":"$165.0 million","upfrontCash":"$15.0 million","newsHeadline":"Relmada Therapeutics Announces the Acquisition of Novel Psilocybin and Derivates","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Relmada Therapeutics"},{"orgOrder":0,"company":"University of California","sponsor":"AmbioPharm","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AmbioPharm Inc. Working with University of California Davis to Develop Non-Opioid Peptide-Based Pain Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Peptide","graph2":"University of California"},{"orgOrder":0,"company":"Aphios","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aphios Granted Chinese Patent for Novel Bryoid to Treat Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Aphios"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Shows Multiple Inflammasomes Combine to Cause Lupus, Macular Degeneration and Other Neuroinflammatory Diseases Such as Alzheimer\u2019s Disease and Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Inflammasome Therapeutics"},{"orgOrder":0,"company":"Zhittya Genesis Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhittya Genesis Medicine Starts Parkinson\u2019s Disease Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Zhittya Genesis Medicine"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acura Pharmaceuticals Provides Development Update on LTX-03","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Acura Pharmaceuticals"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Abuse Deterrent Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acura Pharmaceuticals and AD Pharma Amend License to LIMITx\u2122 LTX-03","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Acura Pharmaceuticals"},{"orgOrder":0,"company":"Enveric Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Enveric Biosciences"},{"orgOrder":0,"company":"Elysium Health","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elysium Health\u2122 Announces Research Partnership with the University of Oxford for the Purpose of Developing Epigenetic Measures of Brain Aging and Health","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Elysium Health"},{"orgOrder":0,"company":"Fathom Pharma","sponsor":"Consegna Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Consegna Pharma Acquires Fathom Pharma to Strengthen Initiatives that Address the Opioid Crisis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Fathom Pharma"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scribe Therapeutics Expands Collaboration With Biogen to Second Target","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Scribe Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"JOS Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Signs Agreement with JOS Pharmaceuticals to Develop Fast-Dissolve Zydis\u00ae Formulation for Cannabidiol as an Anesthesia Premedication","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Catalent Pharma Solutions"},{"orgOrder":0,"company":"MycoMedica Life Sciences","sponsor":"Obvious Ventures","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"MycoMedica Life Sciences, PBC Secures $60 Million in Funding To Fuel Fungi-Based Drug Development for Prevention and Treatment of Psychiatric and Neurological Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"MycoMedica Life Sciences"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Carnegie Mellon University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carnegie Mellon Exosome Engineering Tech Licensed to Coya Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Coya Therapeutics"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Presents Data on Benztropine Use Among People Treated with Antipsychotics at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Neurocrine Biosciences"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Parkinson\u2019s Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NKGen Biotech Announces Collaboration with the Parkinson\u2019s Foundation to Bring Its Novel Natural Killer Cell Therapy to the Clinic for Advanced Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"NKGen Biotech"},{"orgOrder":0,"company":"Halberd Corporation","sponsor":"Hamden Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Halberd Signs Development and Marketing Agreement for Medications & Nutraceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Halberd Corporation"},{"orgOrder":0,"company":"Redpin Therapeutics","sponsor":"Kriya Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kriya Acquires Redpin Therapeutics, Adding Neurology Pipeline to Gene Therapy Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Redpin Therapeutics"},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"PharmAla Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mindset Pharma and PharmAla Enter into Exclusive Sales Agreement for the Sale and Distribution of Pharmaceutical Grade Psilocybin","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Mindset Pharma"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
The acquisition serves as the foundation for Kriya’s neurology therapeutic area portfolio, with two lead gene therapy programs focused on epilepsy and trigeminal neuralgia (TN).
Under the sales agreement, PharmAla will be the exclusive global reseller of Mindset’s cGMP (i.e. pharmaceutical grade) psilocybin to appropriately licensed clinical researchers.
Under this agreement, Hamden will have worldwide exclusive rights to sell, market and distribute the HALB patented low-dose Naltrexone medication, and the HALB proprietary Vita-Shield-Max TM Nutraceutical Product.
NKGen Biotech's non-genetically modified, enhanced, and expanded NK cells (SNK01) is currently in clinical trials for advanced refractory solid tumors both as a monotherapy and in combination with other agents, including checkpoint inhibitors and cell engagers.
Benztropine is an anticholinergic medication approved as an adjunct for treatment of all forms of parkinsonism, including drug-induced parkinsonism that causes movement problems similar to those seen in Parkinson's disease, such as tremors, slow movement, and stiffness.
The exclusive option agreement involves the intellectual property rights to the research, development, and manufacturing of exosome-polymer hybrids (EPHs), a tether-based exosome functionalization strategy that enables Treg exosomes to be homed to proteins of interest.
The proceeds from the financing will be used to advance the company’s next stage of operations having psilocybine on the path to FDA approval for an Investigational New Drug Application (IND) – pre-clinical research and initial clinical trials of the Stamets Stack.
The expanded collaboration further validates Scribe’s position as a leading organization driving the development of novel CRISPR-based therapeutics that treat the underlying cause of disease.
Fathom joining Consegna, will accelerate the clinical development of combined LAI (long-acting injectables) focused on several aspects of pain signaling pathways. Fathom Pharma develops new treatments for chronic pain that includes FP01, as a treatment paradigm.
Developing Elysium Health's proprietary algorithmic platform for epigenetic examination (APEX), and the company's biological age measure Index, Elysium Health plans to utilize the VITACOG biobank to explore the development and commercialization of novel brain health measures.
Lead Product(s):
Micronutrient-based Dietary Supplement
Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
